Enabled formulations: where copying gets technically hard
A conventional tablet is difficult to reconstruct well - but most of its mechanics are understood. Enabled formulations are a different game: products built on a specific technology to drag a difficult molecule into absorption. The formula alone is not the product; the technology is. That is exactly why the dossier for one is worth more.
The four families / and what each is for
The drug is held amorphous - dissolved at the molecular level inside a polymer matrix - instead of crystalline. Made by spray drying (SDD) or hot-melt extrusion (HME). Solubility jumps an order of magnitude or more. The copy problem: the polymer, drug load, and process window determine whether the amorphous phase holds or recrystallizes - get any of them wrong and the product fails stability, not just dissolution.
The drug is milled to particles in the nanometer range, massively increasing surface area and dissolution rate. Wet bead-milling is the standard route, with a stabilizer system keeping the crystals from re-aggregating. The copy problem: particle size distribution, stabilizer identity and level, and mill parameters are the product - and none of them are on the label.
The drug is carried in oils, surfactants, and cosolvents - self-emulsifying systems (SEDDS/SNEDDS) or lipid solutions - filled into softgels. Digestion keeps the drug solubilized through absorption. The copy problem: the lipid composition and HLB balance dictate how the system behaves in the gut, and a small shift in surfactant level can collapse the emulsion.
Some drugs - peptides especially - cannot cross the gut wall at all without help. Permeation enhancers (SNAC is the best-known) transiently raise local pH and membrane permeability so the molecule gets through. The copy problem: the enhancer's amount, release timing, and local concentration sit at the core of whether the product absorbs at all.
What changes in the evidence
The same de-risking ladder applies - provenance-graded reconstruction, f2 dissolution similarity across media, virtual bioequivalence where the physiology supports modeling - but enabled products lean harder on mechanistic detail. An ASD dossier needs the polymer-drug miscibility argument; a nanocrystal dossier needs the milling parameter window; a lipid dossier needs the dispersion behavior on dilution. Equivalence evidence for these products is less a formality and more a technical argument, which is why the dossier reads like a development program, not a data sheet.
The Lawsone asset registry covers all four families - an amorphous dispersion tablet, an ASD softgel-tablet pair, a lipid softgel, a nanocrystal tablet, and a permeation-enhanced peptide - each with the same provenance and simulation standards.